MedHeads

Insomnia and sleep apnoea often occur together, a combination known as COMISA. When both are present, fragmented sleep, low oxygen and repeated stress responses can compound cardiovascular risk far beyond either condition alone.

This episode explains why treating only one side may leave symptoms behind, and how sleep apnoea therapy alongside cognitive behavioural therapy for insomnia can improve sleep and reduce risk.

Erythritol and other low-calorie sweeteners avoid the glucose rise caused by sugar, but that does not make every option risk-free. This episode examines studies linking erythritol and xylitol with increased platelet activity and possible cardiovascular risk, alongside evidence about sucralose and the gut microbiome.

These findings do not prove that an occasional serving causes a heart attack. They do show why dose, frequency and the quality of the evidence matter, and why gradually reducing overall sweetness may be more useful than endlessly replacing sugar.

Cholesterol assessment is changing. This episode explains why newer risk tools look beyond a simple ten-year estimate and how ApoB measures the number of cholesterol-carrying particles rather than only the cholesterol inside them.

It also covers lipoprotein(a), longer-term cardiovascular risk and the situations where extra testing may clarify decisions about prevention. The useful question is not whether one number is “good” or “bad”, but what the full pattern says about risk over time.

Stevia, monk fruit and allulose are often treated as interchangeable sugar substitutes, but they differ in evidence, ingredients and how they behave in food. This episode compares their effects on blood glucose, calorie intake and taste, including the early research around allulose and GLP-1.

It also explains why honey, maple syrup and coconut sugar still count as sugar metabolically, and why the ingredient list matters when commercial sweetener products contain fillers or blends.

Metformin is widely used and generally well tolerated, but its side effects extend beyond the familiar stomach upset. This episode explains metallic taste, nasal symptoms, headaches and the longer-term risk of vitamin B12 deficiency, which can appear as fatigue, numbness or mood changes.

It also covers practical ways clinicians manage gastrointestinal effects and the rare but serious risk of lactic acidosis. Persistent or severe symptoms deserve medical review, especially in people with kidney, liver or heart problems.

Your body clock regulates far more than sleep. This episode explains how circadian timing affects metabolism, immune function and cardiovascular health, and why an irregular weekly schedule can create “social jetlag”.

Morning light, regular meal timing and a consistent wake time are three practical signals that help synchronise the body’s internal clocks. The evidence also shows why eating and sleeping at very different times across the week can make glucose control and weight management harder.

Ultra-processed food leaves a measurable chemical signature in the blood. This episode looks at the metabolites and fatty acids associated with higher intake, and how those changes relate to inflammatory markers including CRP, interleukin-6 and TNF-alpha.

Large population studies also link high ultra-processed food consumption with increased mortality risk. The encouraging part is that blood chemistry can shift when diet changes, making these findings useful for understanding both risk and recovery.

Ibogaine has moved from a banned psychedelic to a serious subject of research into traumatic brain injury, PTSD and opioid dependence. This episode examines what the early clinical evidence shows, including the striking results reported in special operations veterans and the signals emerging from opioid-use trials.

It also covers the major unresolved issue: ibogaine can disrupt the heart’s electrical rhythm and requires careful screening and medical monitoring. The science is promising but still developing, and regulatory interest is accelerating faster than the evidence base.

Probiotics are often recommended after antibiotics, but some research suggests they may delay the return of a person’s own gut microbiome. This episode examines direct endoscopy evidence, why many probiotic strains fail to colonise, and how introduced bacteria can compete with the native community during recovery.

The evidence is more useful when it is specific. Certain strains can reduce severe antibiotic-associated diarrhoea and may help selected people with IBS or a high risk of C. difficile. For many healthy adults, fibre, varied plant foods and fermented foods have stronger practical support than a general-purpose supplement.

GLP-1 medicines such as semaglutide and tirzepatide can produce substantial weight loss, but much of that weight often returns after treatment stops. This episode explains how these drugs affect appetite, stomach emptying and insulin, why regain reflects biology rather than failed willpower, and what major clinical trials have found.

We also examine nausea and gastrointestinal effects, gallstone risk, the thyroid-cancer warning, the practical question of long-term treatment, and early research into alcohol cravings. GLP-1 medicines clearly work while people take them; the harder decision is whether the costs, injections and risk profile fit an individual patient’s long-term care.